glp-1 with no gallbladder Glp1 #metabolism #gallstones #weightloss Semaglutide and No Gallbladder: Safety

CHTD6 CONOTRUNCAL HEART MALFORMATIONS

doi: 10.1080/17512433.2017.1292125 157 FrssingSNylanderMChabanovaEFrystykJHolstJJKistorpCet al

This reduces oxygen use and energy production [5]

13 Inclusion criteria: The sample included adults (age 18 years) with 13 : 1 inpatient primary MS diagnosis or 2 outpatient MS diagnoses in any position 30 days apart in the 12 months prior to (preindex period) or 6 months following the index date First claims were recorded on or after the index date of August 20, 2020, and continuous enrollment in a commercial insurance plan 12 months before and 24 months after the index date The index date was defined as the date of the first KESIMPTA or Ocrevus claim, which was by design after the KESIMPTA US Food and Drug Administration approval on August 20, 2020 Optum Clinformatics Data Mart Database is a longitudinal database of medical and pharmacy administrative claims for patients enrolled in commercial insurance and Medicare Advantage plans in the United States

It includes incretin-based therapies where primary clinical positioning centers on weight management and excludes GLP-1 drugs prescribed solely for glycemic control without a labeled obesity indication